Literature DB >> 19760651

Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome.

John M Graham1, Nancy Kramer, Bassem A Bejjani, Christian T Thiel, Claudio Carta, Giovanni Neri, Marco Tartaglia, Martin Zenker.   

Abstract

Noonan syndrome (NS) is a genetically heterogeneous disorder caused most commonly by activating mutations in PTPN11. We report a patient with hypotonia, developmental delay and clinical features suggestive of NS. High-resolution chromosome analysis was normal, and sequence analyses of PTPN11, SOS1, KRAS, BRAF, RAF1, MEK, and MEK2 were also normal. Array CGH revealed a single copy gain of 9 BAC clones at 12q24.11q24.21 (8.98 Mb in size), which encompassed the PTPN11 locus at 12q24.13 and was confirmed by FISH analysis. Shchelochkov et al. [Shchelochkov et al. (2008); Am J Med Genet Part A 146A:1042-1048] reported a similar case and speculated that such duplications might account for 15-30% of NS cases with no detectable mutation in NS genes. We screened more than 250 NS cases without mutation in known NS disease-causing genes by quantitative PCR, and none of these studies produced results in the duplicated range. We also explored the possibility that de novo changes affecting the untranslated region (UTR) of the PTPN11 transcript might represent an alternative event involved in SHP2 enhanced expression. DHPLC analysis and direct sequencing of the entire 3' UTR in 36 NS patients without mutation in known genes did not show any disease-associated variant. These findings indicate that duplications of PTPN11 represent an uncommon cause of NS, and functionally relevant variations within the 3'UTR of the gene do not appear to play a major role in NS. However, recurrent observations of NS in individuals with duplications involving the PTPN11 locus suggest that increased dosage of SHP2 may have dysregulating effects on intracellular signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760651      PMCID: PMC2768228          DOI: 10.1002/ajmg.a.32992

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  33 in total

1.  Clinical and molecular studies in a large Dutch family with Noonan syndrome.

Authors:  I van der Burgt; E Berends; E Lommen; S van Beersum; B Hamel; E Mariman
Journal:  Am J Med Genet       Date:  1994-11-01

2.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Authors:  Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2002-05-01       Impact factor: 11.025

3.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

4.  De novo pure 12q22q24.33 duplication: first report of a case with mental retardation, ADHD, and Dandy-Walker malformation.

Authors:  S Cappellacci; S Martinelli; R Rinaldi; E Martinelli; P Parisi; B Mancini; R Pescosolido; P Grammatico
Journal:  Am J Med Genet A       Date:  2006-06-01       Impact factor: 2.802

5.  Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.

Authors:  Simone Martinelli; Paola Torreri; Michele Tinti; Lorenzo Stella; Gianfranco Bocchinfuso; Elisabetta Flex; Alessandro Grottesi; Marina Ceccarini; Antonio Palleschi; Gianni Cesareni; Luisa Castagnoli; Tamara C Petrucci; Bruce D Gelb; Marco Tartaglia
Journal:  Hum Mol Genet       Date:  2008-03-27       Impact factor: 6.150

6.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

Review 7.  Mosaicism for duplication 12q (12q13-->q24.2) in a dysmorphic male infant.

Authors:  J W Dixon; T Costa; I E Teshima
Journal:  J Med Genet       Date:  1993-01       Impact factor: 6.318

8.  A new quantitative PCR multiplex assay for rapid analysis of chromosome 17p11.2-12 duplications and deletions leading to HMSN/HNPP.

Authors:  Christian T Thiel; Cornelia Kraus; Anita Rauch; Arif B Ekici; Bernd Rautenstrauss; André Reis
Journal:  Eur J Hum Genet       Date:  2003-02       Impact factor: 4.246

9.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.

Authors:  Marco Tartaglia; Simone Martinelli; Giovanni Cazzaniga; Viviana Cordeddu; Ivano Iavarone; Monica Spinelli; Chiara Palmi; Claudio Carta; Andrea Pession; Maurizio Aricò; Giuseppe Masera; Giuseppe Basso; Mariella Sorcini; Bruce D Gelb; Andrea Biondi
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication.

Authors:  Blake C Ballif; Aaron Theisen; Justine Coppinger; Gordon C Gowans; Joseph H Hersh; Suneeta Madan-Khetarpal; Karen R Schmidt; Raymond Tervo; Luis F Escobar; Christopher A Friedrich; Marie McDonald; Lindsey Campbell; Jeffrey E Ming; Elaine H Zackai; Bassem A Bejjani; Lisa G Shaffer
Journal:  Mol Cytogenet       Date:  2008-04-28       Impact factor: 2.009

View more
  10 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 2.  Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.

Authors:  Mary Ella M Pierpont; Pilar L Magoulas; Saleh Adi; Maria Ines Kavamura; Giovanni Neri; Jacqueline Noonan; Elizabeth I Pierpont; Kent Reinker; Amy E Roberts; Suma Shankar; Joseph Sullivan; Melinda Wolford; Brenda Conger; Molly Santa Cruz; Katherine A Rauen
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

Review 3.  Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Ann N Y Acad Sci       Date:  2010-10-19       Impact factor: 5.691

4.  Low Efficacy of Genetic Tests for the Diagnosis of Primary Lymphedema Prompts Novel Insights into the Underlying Molecular Pathways.

Authors:  Gabriele Bonetti; Stefano Paolacci; Michele Samaja; Paolo Enrico Maltese; Sandro Michelini; Serena Michelini; Silvia Michelini; Maurizio Ricci; Marina Cestari; Astrit Dautaj; Maria Chiara Medori; Matteo Bertelli
Journal:  Int J Mol Sci       Date:  2022-07-03       Impact factor: 6.208

5.  Comprehensive Genetic Analysis of RASopathy in the Era of Next-Generation Sequencing and Definition of a Novel Likely Pathogenic >KRAS Variation.

Authors:  Selma Demir; Hümeyra Yaşar Köstek; Aslıhan Sanrı; Ruken Yıldırım; Fatma Özgüç Çömlek; Sinem Yalçıntepe; Murat Deveci; Emine İkbal Atlı; Engin Atlı; Damla Eker; Hakan Gürkan; Filiz Tütüncüler Kökenli
Journal:  Mol Syndromol       Date:  2022-01-07

6.  Expansion of the RASopathies.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Genet Med Rep       Date:  2016-07-01

7.  Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?

Authors:  M J M Nowaczyk; B A Thompson; S Zeesman; U Moog; P A Sanchez-Lara; P L Magoulas; R E Falk; J E Hoover-Fong; D A S Batista; S M Amudhavalli; S M White; G E Graham; K A Rauen
Journal:  Clin Genet       Date:  2013-04-02       Impact factor: 4.438

8.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Authors:  Gorjan Hrustanovic; Victor Olivas; Evangelos Pazarentzos; Asmin Tulpule; Saurabh Asthana; Collin M Blakely; Ross A Okimoto; Luping Lin; Dana S Neel; Amit Sabnis; Jennifer Flanagan; Elton Chan; Marileila Varella-Garcia; Dara L Aisner; Aria Vaishnavi; Sai-Hong I Ou; Eric A Collisson; Eiki Ichihara; Philip C Mack; Christine M Lovly; Niki Karachaliou; Rafael Rosell; Jonathan W Riess; Robert C Doebele; Trever G Bivona
Journal:  Nat Med       Date:  2015-08-24       Impact factor: 53.440

9.  Rare copy number variations containing genes involved in RASopathies: deletion of SHOC2 and duplication of PTPN11.

Authors:  Jin-Lan Chen; Xin Zhu; Tian-Li Zhao; Jian Wang; Yi-Feng Yang; Zhi-Ping Tan
Journal:  Mol Cytogenet       Date:  2014-04-16       Impact factor: 2.009

10.  Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.

Authors:  Brigitte Gilbert-Dussardier; Audrey Briand-Suleau; Ingrid Laurendeau; Frédéric Bilan; Hélène Cavé; Alain Verloes; Michel Vidaud; Dominique Vidaud; Eric Pasmant
Journal:  Orphanet J Rare Dis       Date:  2016-07-22       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.